

1

2 ***Long-term iron deficiency and iron supplementation***  
3 ***exacerbate acute DSS-induced colitis and are associated***  
4 ***with significant dysbiosis***

5

6

7 **Awad Mahalhal <sup>1,3</sup>, Michael D. Burkitt <sup>1</sup>, Carrie A. Duckworth <sup>1</sup>, Georgina L. Hold <sup>2</sup>, Barry**  
8 **J. Campbell <sup>1</sup>, D. Mark Pritchard <sup>1</sup>, Chris S. Probert <sup>1</sup>**

9

10

11 1. Gastrointestinal Research Unit, Department of Cellular and Molecular Physiology, Institute  
12 of Translational Medicine, University of Liverpool, Liverpool, L69 3GE UK

13 2. Microbiome Research Centre, St George & Sutherland Clinical School, University of New  
14 South Wales, Sydney, NSW, Australia

15 3. Department of Anatomy and Histology, Faculty of Medicine, Benghazi University, Benghazi-  
16 Libya

17

18

19

20

21

22 Correspondence to:

23 Email: [awad.mahalhal@liverpool.ac.uk](mailto:awad.mahalhal@liverpool.ac.uk) (AM)

24

25

26

27

28

29

30 "Authors' contributions."

31

32 **Awad Mahalhal** [conceived and designed research, performed experiments, analysed data, interpreted results of experiments, prepared figures, drafted manuscript, edited and revised manuscript and approved the final version of manuscript]

35 **Carrie A. Duckworth** [conceived and designed research, edited and revised manuscript, approved the final version of the manuscript]

37 **Michael D. Burkitt** [analysed data, edited and revised manuscript, approved the final version of manuscript]

39 **Georgina L. Hold** [analysed data, prepared figures, drafted manuscript, edited and revised manuscript, approved the final version of manuscript]

41 **Barry J. Campbell** [conceived and designed research, interpreted results of experiments, edited and revised manuscript, approved the final version of manuscript]

43 **D. Mark Pritchard** [conceived and designed research, edited and revised manuscript, approved the final version of the manuscript]

45 **Chris S. Probert** [conceived and designed research, analysed data, interpreted results of experiments, edited and revised manuscript, approved the final version of manuscript].

47

48 **Abstract:**

49 Patients taking oral iron supplementation often suffer from gastrointestinal side effects. We  
50 have previously shown that acute alterations in oral iron exacerbate dextran sodium sulphate  
51 (DSS) induced colitis and are associated with dysbiosis. As patients take iron supplementation  
52 for long periods, we asked whether this too would influence colitis and the microbiome. We  
53 assessed the impact of long-term changes in dietary iron, by feeding chow containing 100ppm,  
54 200ppm and 400ppm (reflecting a deficient, normal or supplemented diet, respectively) for up  
55 to 9 weeks to female wild-type C57BL/6 (WT) mice in presence or absence of chronic colitis,  
56 or acute colitis induced after 8 weeks, induced by DSS. Assessment was made based on (i)  
57 clinical and histological severity of colitis, and (ii) faecal microbial diversity, as assessed by  
58 sequencing the V4 region of 16S rRNA. In mice with long term changes to their dietary iron,  
59 reduced iron intake (100ppm iron diet) was associated with increased weight loss and  
60 histology scoring in the acute colitis model. Chronic colitis was not influenced by altering  
61 dietary iron however there was a clear change in the faecal microbiome in the 100 and 400ppm  
62 iron DSS-treated groups and in controls consuming the 400ppm iron diet. Proteobacteria  
63 levels increased significantly at day-63 compared to baseline and Bacteroidetes levels  
64 decreased in the 400ppm iron DSS group at day-63 compared to baseline; mirroring our  
65 previously published work in acute colitis. Long term dietary iron alterations clearly affects gut  
66 microbiota signatures but do not appear to exacerbate chronic colitis. However, acute colitis  
67 is exacerbated by changes in dietary iron. More work is needed to understand the impact of  
68 iron supplementation of the pathogenesis of IBD and rise that possibility that the change in  
69 the microbiome, in patients with colitis, is a consequence of the increase in luminal iron and  
70 not simply the presence of colitis.

## 72 Introduction

73 Inflammatory bowel disease (IBD) is a debilitating, relapsing-remitting long-term condition of  
74 the gastrointestinal tract that affects around 240,000 people in the UK (1) (2, 3). Approximately  
75 one-third of patients develop iron deficiency anaemia because of intestinal bleeding and/or  
76 malabsorption (4-7). Iron deficiency (ID) may be treated effectively by intravenous or oral iron  
77 replacement (8). These therapeutic options have different side effect profiles (9), and may  
78 have other off target effects e.g. iron is a growth factor for some bacteria (10). Unabsorbed  
79 oral iron supplements and gastrointestinal bleeding result in an increase in luminal iron which  
80 may exacerbate IBD and lead to increased proliferation and virulence of some bacteria (11-  
81 13). Intestinal bacterial dysbioses have been associated with relapse of IBD (14, 15). It is not  
82 clear whether relapsing inflammation leads to dysbiosis by modulating luminal iron (16).

83

84 Chronic inflammation of the intestinal tract is the main feature of IBD. Intestinal epithelial cells  
85 (IECs) provide a single superficial layer on the intestinal mucosa and act as the first defensive  
86 barrier against the luminal content of the gut and protector of the underlying tissues. IECs  
87 have important roles, secreting antimicrobial substances [defensins] and communicating with  
88 intestinal immune cells using soluble mediators, chemokines and cytokines (17, 18). There is  
89 mounting evidence that alterations in immune regulatory pathways, including inflammasome  
90 activation pathways drive changes in gut microbial diversity (19). The mucosal barrier not  
91 only defends against luminal pathogens, but also actively shapes the peri-mucosal niche,  
92 thereby regulating the composition of the mucosa-associated microbiota (20).

93

94 Based on this evidence, we hypothesised that iron supplementation (and or bleeding) in IBD  
95 patients could change the composition of the gut microbiota and potentially influence the  
96 natural history of IBD. To investigate this, we assessed the long-term effects of altering dietary  
97 iron consumption on intestinal microbiota in murine models of colitis to eliminate any  
98 confounding factors based on background genetics that would be inevitable in a human  
99 population.

100 **Materials and Methods**

101 **Animals**

102 Wild type C57BL/6 female mice, aged 8-9 weeks old, were purchased from Charles River  
103 Laboratories (Margate, UK). Six groups of 8 mice were studied: three control groups and three  
104 DSS-treated groups, all of which were maintained for 63-days. Mice received standard chow  
105 and water *ad libitum*, during an acclimatisation period of at least one week. Animals were then  
106 individually caged in a room with controlled temperature, humidity and a pre-set dark-light  
107 cycle (12 h: 12 h) in a specific pathogen-free animal facility. For each group of experiments,  
108 mice were matched for age and body weight. The care of, and experimentation on, mice was  
109 carried out in accordance with UK Home Office regulations (project licence no: 70/8457) and  
110 the project was reviewed by the University of Liverpool Animal Welfare and Ethical Review  
111 Body (AWERB).

112

113 **Diets**

114 When eating a normal (standard) iron diet, mice were fed Rat and Mouse Breeder and Grower  
115 Pelleted CRM (P) chow (Special Diets Services (SDS), Witham, Essex, UK) which contained  
116 200 part per million (ppm) iron in 10mm compression pellets. Two modifications of this  
117 standard iron diet were also used: the first was CRM (P) 100ppm iron (Fe) diet where the CRM  
118 (P) formulation was used with reduced iron content (0.01% Fe), this was called the half  
119 standard iron diet (100ppm iron). The second modification was the CRM (P) 400ppm iron diet:  
120 again the CRM (P) formulation was used, but the iron content was increased (0.04% Fe), this  
121 was called the double standard iron diet (400ppm iron).

122

123 **Controls**

124 Mice in the three control groups received the standard, half standard or double standard iron  
125 diets respectively for 63 days. After 53-days, each group was divided into two, half carried on  
126 as controls and half were treated with 2% DSS as described below (Supplementary Figure 1).

127

128 **Induction of chronic colitis using dextran sodium sulphate  
(DSS)**

130 Three groups of 8 mice (taking standard, half standard and double standard iron diets  
131 respectively) were given a 1.25% solution of dextran sulfate sodium (M.W. 36,000 – 50,000Da;  
132 Catalogue number: 160110; Lot number: 6683K; MP Biomedicals, LLC, UK) in their drinking  
133 water for 5-days to induce colitis (Supplementary Figure 1). Mice were allowed to recover for  
134 16 days and then the DSS-treatment was repeated for a total of three cycles (21).

135

136 **Induction of acute colitis using DSS**

137 Three groups of 4 mice which had been on the diets for 53 days (control groups) received 2%  
138 DSS for 5-days in drinking water, followed by 5-days of plain drinking water, to induce acute  
139 colitis. All mice were euthanised on day-63.

140

141 **Histopathological scoring of colonic inflammation**

142 The distal colon was removed, fixed in 4% neutral buffered formalin, dehydrated, wax-  
143 embedded and then cut into 4 $\mu$ m sections. The sections were stained with haematoxylin and  
144 eosin (H&E). Inflammation was reported using the inflammatory scoring system described by  
145 Bauer *et al.* (22). Fibrosis was assessed using Masson's trichrome staining (NovaUltra<sup>TM</sup>  
146 Masson's Trichrome Stain Kit (Fisher Scientific UK Ltd)) (23). A researcher blinded to the  
147 treatment group assessed all slides.

148

## 149 **Assessing the degree of gut inflammation by measuring** 150 **faecal calprotectin concentrations**

151 Faecal calprotectin concentration was measured using the S100A8/S100A9 ELISA kit  
152 (Immundiagnostik AG, Stubenwald-Allee 8a, Bensheim, Germany) from faecal samples  
153 collected from each mouse, on day-1, 21, 42 and 63 in the chronic colitis study, and on day-1  
154 and day-10 of the acute colitis study in control mice.

155

156

157

## 158 **Faecal iron concentration**

159 The faecal iron ( $Fe^{2+}$  and  $Fe^{3+}$ ) concentration was measured using an iron immunoassay kit  
160 (MAK025, Sigma-Aldrich) from the same faecal pellets that were collected for calprotectin  
161 assessment.

162

## 163 **Faecal bacterial DNA extraction and sequencing**

164 2g of faeces was used for bacterial DNA extraction using Stratec Kit (PSP® Spin Stool DNA  
165 Plus Kit, STRATEC Molecular GmbH, D-13125 Berlin) following the supplier's protocol. The  
166 extracted DNA was sent to the Centre for Genomic Research at the University of Liverpool to  
167 undertake the rest of amplicon library protocol 16S [Metagenomic Sequencing Library].  
168 Primers described by Caporaso *et al.* (24) were used to amplify the V4 region of 16S rDNA F:  
169 5'ACACTCTTCCCTACACGACGCTCTCCGATCTNNNNNGGCCAGCMGCCGCGGTAA  
170 3' and R: 5'GTGACTGGAGTTCAGACGTGTGCTCTCCGATCTGG  
171 ACTACHVGGGTWTCTAAT3'.

172

173 Approximately 5  $\mu$ g of extracted DNA was used for first round PCR with conditions of 20 sec  
174 at 95°C, 15 secs at 65°C, 30 sec at 70°C for 10 cycles then a 5 min extension at 72°C. Samples  
175 were purified using Axygen SPRI Beads. The second-round PCR was performed to

176 incorporate Illumina sequencing adapter sequences: 15 cycles of PCR were performed using  
177 the same conditions. Samples were re-purified then quantified using Qubit and assessed using  
178 the Fragment Analyser. Successfully-generated amplicon libraries were sequenced (25).

179

180 The final libraries were pooled in equimolar amounts using the Qubit and Fragment Analyser  
181 data and 350-550 bp size-selected on the Pippin Prep. The quantity and quality of each pool  
182 were assessed by Bioanalyzer and subsequently by qPCR using the Illumina Library  
183 Quantification Kit from Kapa on a Roche Light Cycler LC480II according to manufacturer's  
184 instructions. The pool of libraries was sequenced on one lane of the MiSeq at 2x250 bp paired-  
185 end sequencing. To help balance the complexity of the amplicon library 15%, PhiX was spiked  
186 in (25).

187

## 188 **Bioinformatics analysis**

189 Initial processing and quality assessment of the sequence data was performed using an in-  
190 house pipeline. Base-calling and de-multiplexing of indexed reads were conducted by  
191 CASAVA version 1.8.2 (Illumina). The raw fastq files were trimmed to remove Illumina adapter  
192 sequences where any reads that matched the adapter sequence over at least three bp was  
193 trimmed off. The reads were further trimmed to remove low-quality bases (reads <10 bp were  
194 removed). Read pairs were aligned to produce a single sequence for each read pair that would  
195 entirely span the amplicon. Sequences with lengths outside the expected range were excluded  
196 (25). The sequences passing the above filters for each sample were pooled into a single file.  
197 A metadata file was created to describe each sample. These two files were analysed using  
198 Qiime, version 1.8.0 (Caporaso *et al.*, 2010) (26). Similar sequences were clustered into  
199 groups, to define OTUs of 97% similarity. OTU-picking was performed using USEARCH7  
200 (Edgar *et al.*, 2010) (27). The Greengenes database version 12.8 (McDonald *et al.*, 2012) (28),  
201 was used for reference-based chimaera detection (25). OTU tables were repeatedly  
202 sub-sampled (rarefied). For each rarefied OTU table, three measures of alpha diversity were  
203 estimated: chao1, the observed number of species, and the phylogenetic distance. For

204 inter-sample comparisons (beta-diversity), all datasets were rarefied, and tables were used to  
205 calculate weighted and unweighted pair-wise UniFrac matrices using Qiime. UniFrac matrices  
206 were then used to generate UPGMA (Unweighted Pair-Group Method with Arithmetic mean)  
207 trees and 2D principal coordinates plots (PCoA).(25)

208

## 209 **Statistics**

210 Normally distributed physiological and biochemical data were assessed by analysis of  
211 variance followed by multiple comparisons Dunn's test and non-normally distributed data  
212 have been evaluated by Kruskal-Wallis test followed by multiple comparisons Dunn's test  
213 (Stats Direct version 3.0.171). For the bioinformatic analysis of microbiota data, Kruskal-  
214 Wallis H-test was used with the false discovery rate (FDR) Storey's (multiple correction tests).  
215 The q-value is the adjusted p-value based on FDR calculation, where statistical significance  
216 was declared at p<0.05.

217 **Results**

218 **Chronic DSS-induced colitis induces C57BL/6 weight loss**

219 Colitis was reproducibly induced by 1.25% DSS. All mice lost body weight from day-6 and  
220 maximal weight loss occurred at day-8 of each cycle. Mice receiving the 100ppm iron diet  
221 appeared to lose more weight than other groups, but this difference was not significant (Fig.  
222 1-a). All control mice, irrespective of the iron dosing, showed a steady increase in body weight.  
223 However, mice fed 400ppm iron diet showed a significant weight gain during the whole 63  
224 days this reflect the nutritional factor effect (Supplementary Figure 2).

225

226 **Figure 1-a: Percentage of weight change in mice (100ppm iron (blue), 200ppm iron (red)**  
227 **and 400ppm iron (green)) during three cycles of 1.25% dextran sulphate sodium-**  
228 **induced colitis during the 63-day period. Data are presented as a mean ± standard error**  
229 **of the mean. Statistical differences were assessed by the Kruskal–Wallis test followed**  
230 **by Dunn's multiple comparison tests. (n=8 female mice per group).**

231

232 **Acute DSS-colitis induced weight loss is more severe in**  
233 **mice fed 100ppm iron diets**

234 Acute DSS colitis was induced after 53 days of dietary manipulation in a subset of mice that  
235 had consumed different amounts of dietary iron during this time: all developed colitis.  
236 Weight loss began earlier (day-3) in the 100ppm iron group than in the 200 and 400ppm  
237 iron DSS-treated groups (Fig. 1-b). During this acute DSS cycle, mice fed 100ppm iron lost  
238 significantly ( $P<0.001$ ) more weight than the other treated groups.

239

240 **Figure 1-b: Percentage of weight change in mice (100ppm iron (blue), 200ppm iron (red)**  
241 **and 400ppm iron (green)) during 2% dextran sulphate sodium-induced colitis. Data are**  
242 **presented as a mean ± standard error of the mean. Statistical differences were assessed**

243 by the Kruskal–Wallis test followed by Dunn's multiple comparison tests, compared  
244 with standard chow group. (n=4 female mice per group). \* P<0.05, \*\* P<0.01, \*\*\* P<0.001.

245

246 **Histopathological changes caused by acute and chronic**  
247 **DSS treatment**

248 At autopsy all mice that had been treated with repeated cycles of 1.25% DSS showed  
249 histological evidence of mild chronic colitis (Fig. 2-a; I, II and III), and those receiving acute  
250 DSS treatment had moderately severe acute colitis (Fig. 2-a; VII, VIII and IX). By contrast the  
251 colons of control untreated mice appeared histologically normal (Fig. 2-a; IV, V and VI). The  
252 colitis scores were significantly greater (P<0.01) in the mice that had been treated with 2%  
253 DSS after consuming either 100 or 400ppm iron, compared with the mice that had received  
254 200ppm iron and all the mice that received cycles of 1.25% DSS (Fig. 2-b).

255

256 **Figure 2-a: Illustrative H&E-stained segments of distal colon from untreated (n=4),**  
257 **1.25% (n=8) and 2% DSS-treated mice (n=4). Mice received either water (control) (IV, V,**  
258 **VI), 1.25% DSS for 5 days and full recovery period 16 days on normal water (I, II, III) or**  
259 **2% DSS for 5 days and followed by another 5 days on plain drinking water before they**  
260 **were euthanised (VII, VIII, IX). Arrowheads highlight submucosal oedema; arrows**  
261 **highlight almost complete loss of colonic epithelium. Scale Bar: 100 µm.**

262 **Figure 2-b: Inflammation (colitis) scores for all groups' DSS-treated (n=8 (63-days) and**  
263 **n=4 (10-days) mice per group) and untreated (controls) mice on different iron diets n=4**  
264 **per group (63-days). Horizontal lines at the median. Differences tested by One-way**  
265 **ANOVA followed by multiple comparisons Dunn's test. \*\*P<0.01.**

266

267

268 **Analysis of intestinal fibrosis in chronic colitis in mice**  
269 **treated with repeated cycles of dextran sulphate sodium**

270 Masson's trichrome staining was used to assess the degree of fibrosis following chronic DSS  
271 treatment (Supplementary Figure 3). Mice in the 100ppm iron DSS-treated group had  
272 significantly more fibrosis ( $P<0.05$ ) than the DSS-treated mice receiving 200ppm iron and  
273 400ppm iron diets (Supplementary Figure 4).

274

275 **Faecal calprotectin concentration in chronic and acute DSS-  
276 treated mice**

277 Faecal calprotectin concentrations appeared to increase after each cycle of 1.25% DSS  
278 treatment in mice consuming the 400ppm iron diet; the differences were statistically significant  
279 ( $P<0.01$ ) between day-21 and day-63 (Supplementary Figure 5): this was not seen in other  
280 mice. Thus, mice with double standard iron diet appeared to develop more inflammation at  
281 molecular level by assessment of faecal calprotectin concentration.

282

283 For the acute DSS experiment, faecal calprotectin concentration increased significantly in  
284 each DSS-treated group. The change in faecal calprotectin was greater in the 100ppm iron  
285 diet DSS-treated mice than in the other groups (Supplementary Figure 6). Thus, mice  
286 consuming half-standard iron diets also appeared to develop more molecular inflammation  
287 after acute colitis induced.

288

289 **Faecal iron concentrations**

290 In the chronic colitis experiment, DSS-treated mice consuming 400ppm iron showed a  
291 difference in faecal iron concentration between day-1 and day-63 only. Mice in the 100 and  
292 200ppm treated groups that received DSS both showed significant differences at day-1 vs  
293 day-21, 42 and 63 (Fig. 3-a) consistent with the presence of luminal iron from bleeding

294 resulting from colitis. Faecal iron concentration increased significantly in control mice (63 days  
295 on diet alone) taking 200 and 400ppm diets, but did not change with time in those mice  
296 consuming 100ppm iron (Fig. 3-a).

297

298 In the acute DSS experiment, faecal iron concentration increased significantly in all DSS-  
299 treated mice. This was more pronounced in the 400ppm iron group (Fig. 3-b).

300

301 **Figure 3-a: Faecal iron concentration at four different time points day-1, 21, 42 and 63**  
302 **separately. (I) Faecal iron in 100ppm iron DSS-treated and untreated groups (II) faecal**  
303 **iron in 200ppm iron DSS-treated and untreated groups (III) faecal iron in 400ppm iron**  
304 **DSS-treated and untreated groups. Data are presented as a mean ± standard error of**  
305 **the mean. Differences were tested by Kruskal– Wallis test followed by multiple**  
306 **comparison Dunn's test. \*\* P<0.01.**

307 **Figure 3-b: Faecal iron concentration at two different time points day-1 and 10**  
308 **separately. (I) Faecal iron in 100ppm iron DSS-treated and untreated groups (II) faecal**  
309 **iron in 200ppm iron DSS-treated and untreated groups (III) faecal iron in 400ppm iron**  
310 **DSS-treated and untreated groups. Data are presented as a mean ± standard error of**  
311 **the mean. Differences were tested by Kruskal– Wallis test followed by multiple**  
312 **comparison Dunn's test.**

313

314

315 **Bacterial diversity data analysis at phylum and family level**  
316 **for chronic experiments**

317 Tables of rarefied OTU data were prepared, and three measures of alpha diversity were  
318 estimated: chao1, the observed number of species, and the phylogenetic distance. These  
319 estimates were plotted as rarefaction curves using Qiime (Supplementary Figure 7). Similarly,  
320 for beta-diversity, weighted and unweighted pair-wise UniFrac matrices UPGMA trees were  
321 prepared (Supplementary Figure 8).

322  
323 Principal component analysis (PCA) was used to identify linear combinations of gut microbial  
324 taxa associated with the duration on a diet (Fig. 4). Our data showed an overlap in the samples  
325 of 100 and 200ppm iron DSS-untreated and 200ppm iron DSS-treated mice (Figure 4-a, c and  
326 d). There was clustering with little separation of samples pre- and post-DSS treatment for 100  
327 and the 400ppm iron DSS-treated groups as well as with control mice fed a 400ppm iron diet  
328 (Figure 4-b, e and f). The double standard (400ppm) iron diet disturbed the microbial  
329 community significantly in both DSS-treated and untreated mice.

330  
331 **Figure 4: In chronic DSS, PCA plots of the unweighted UniFrac distances of pre-and**  
332 **post-DSS-intervention stool samples from chronic (3 cycles) DSS-treated mice (b, d,**  
333 **and f) and (a, c and e) untreated mice at Phylum-level, phylogenetic classification of**  
334 **16S rRNA gene sequences. Symbols represent data from individual mice, colour-**  
335 **coded by the indicated metadata. Statistical differences were assessed by Kruskal-**  
336 **Wallis H-test followed by Storey's FDR multiple test correction.**

337  
338  
339 Post-hoc tests revealed a significant difference in the amount of *Proteobacteria* in 100ppm  
340 iron chronic DSS-treated mice when day-1 and 63 were compared ( $P<0.017$ ) (Fig. 5-a). In  
341 400ppm iron DSS-untreated mice there was a significant increase in two phyla (*Proteobacteria*  
342 and *Actinobacteria*) comparing day-1, 21, 42 and 63 samples ( $p<0.011$  for both) (Fig. 5-b).  
343 The analysis of faecal samples from mice in the 400ppm iron DSS-treated group showed  
344 differences in *Bacteroidetes* and *Proteobacteria* comparing day-1, 21, 42 and 63:  
345 *Proteobacteria* increased significantly ( $P<0.016$ ), and *Bacteroidetes* decreased ( $P<0.028$ )  
346 (Figure 5-c). Together these data suggest that *Proteobacteria* are dependent on luminal iron,  
347 but *Bacteroidetes* are suppressed by inflammation and/or luminal iron.

348

349 **Figure 5-a: In chronic DSS, box plot showing the distribution in the proportion of**  
350 ***Proteobacteria* assigned to samples at day-1, 21, 42 and 63 from 100ppm iron DSS-**  
351 **treated mice.**

352 **Figure 5-b: In chronic DSS, box plot showing the distribution in the proportion of two**  
353 **phyla (*Actinobacteria* (I) and *Proteobacteria* (II)) assigned to samples from 400ppm**  
354 **iron untreated mice.**

355 **Figure 5-c: In chronic DSS, box plot showing the distribution in the proportion of two**  
356 **phyla (*Proteobacteria* (I) and *Bacteroidetes* (II)) assigned to samples from 400ppm iron**  
357 **DSS-treated mice.**

358

359 Further bioinformatics analysis identified 4 phyla and 15 taxa (genera) of interest. Of the four  
360 phyla (*Firmicutes*, *Bacteroidetes*, *Proteobacteria*, and *Actinobacteria*), one (*Firmicutes*) was  
361 highly abundant among all groups while the lowest abundance phylum was *Actinobacteria*.  
362 However, 100ppm iron and 400ppm iron chronic DSS groups showed seven different genera  
363 apart from the three genera (*Bacteroides*, *Lactobacillus* and *Bilophila*) that they shared.  
364 STAMP encourages the use of effect sizes and confidence intervals (29). The results of the  
365 relative abundances of various phyla and identified genera are summarised in Table 1: a-c.

366

367 **Table 1-a:** Genus-level taxonomic composition of faecal samples from 100ppm iron DSS-  
368 treated mice (Day-1 vs 21, 42 and 63 samples)

100ppm iron DSS-treated group			
Taxon	p-values	p-values (corrected)	Effect size
<b>p_Bacteroidetes; g_Bacteroides</b>	0.003	0.047	0.496
<b>p_Bacteroidetes; g_Odoribacter</b>	0.002	0.04	0.620
<b>p_Bacteroidetes; g_Prevotella</b>	0.0002	0.008	0.669
<b>p_Firmicutes; g_Clostridium</b>	0.002	0.04	0.431
<b>p_Firmicutes; g_Dorea</b>	0.003	0.047	0.138
<b>p_Firmicutes; g_Lactobacillus</b>	0.00002	0.002	0.880
<b>p_Proteobacteria; g_Bilophila</b>	0.0002	0.008	0.766

369 **Table 1-b:** Genus-level taxonomic composition of faecal samples from 400ppm iron DSS-  
370 treated mice (Day-1 vs 21, 42 and 63 samples)

400ppm iron DSS-treated group			
Taxon	p-values	p-values (corrected)	Effect size
<b>p_Firmicutes; g_Lactobacillus</b>	0.0001	0.01	0.74

371  
372

373 **Table 1-c:** Genus-level taxonomic composition of faecal samples from 400ppm iron untreated  
374 mice (Day-1 vs 21, 42 and 63 samples)

400ppm iron untreated group (Controls)			
Taxon	p-values	p-values (corrected)	Effect size
<b>p_Actinobacteria; g_Adlercreutzia</b>	0.002	0.04	0.49
<b>p_Bacteroidetes; g_Bacteroides</b>	0.0005	0.02	0.68
<b>p_Firmicutes; g_Candidatus Arthromitus</b>	0.003	0.04	0.54
<b>p_Firmicutes; g_Lactobacillus</b>	0.0002	0.02	0.77
<b>p_Firmicutes; g_Oscillospira</b>	0.001	0.03	0.61
<b>p_Firmicutes; g_Ruminococcus</b>	0.002	0.04	0.46
<b>p_Proteobacteria; g_Bilophila</b>	0.001	0.03	0.55

375

376

377

378 

## Discussion

379 DSS-induced colitis in mice is a popular model for the study of human ulcerative colitis: its  
380 mechanism of action is unclear but may be toxic to the colonic epithelium, activate  
381 macrophages and/or alter the gut microbiota (30) (31). Most research has used the acute  
382 colitis model, however Okayasu *et al* described a chronic colitis model in mice, which may be  
383 more appropriate for research of chronic IBD in humans (31) (32) (33). Most studies of the role  
384 of iron in relapse of IBD have focussed on the effect of supplementation, however we have  
385 recently reported the effect of half standard and double standard dietary iron on acute DSS  
386 induced colitis: both changes were associated with more severe colitis than the standard diet  
387 (25). Here, we report the effects of the same dietary modification on a model of (1) chronic  
388 colitis and (2) acute colitis, in the setting of chronic prior modification of the diet.

389

390 When acute colitis was induced after 7 weeks of dietary modification, mice consuming the  
391 100ppm or 400ppm diet developed more severe colitis than mice taking the 200ppm iron diet:  
392 clinical and histological data were concordant for 100ppm iron group. In contrast, mice in which  
393 chronic colitis was induced while consuming 100ppm, 200ppm or 400ppm dietary iron showed  
394 only modest, non-significant weight loss and histological colitis.

395

396 In this study, increasing dietary iron led to an increase in faecal iron in the 200 and 400ppm  
397 treated mice. After induction of chronic colitis, faecal iron increased in all mice. In the acute  
398 DSS experiment, the 400ppm iron group showed the most significant difference ( $P<0.0001$ ) in  
399 faecal iron concentration. There is an obvious paradox: reducing dietary iron was associated  
400 with an increase in loss of iron in faeces. The mechanism appears to be by exacerbating DSS-  
401 colitis. We speculate that the low iron diet led to more severe colitis, which secondarily led to  
402 an increase in bleeding and hence faecal iron.

403

404 Changing dietary iron concentration led to a significant difference in the microbiome in both  
405 the 100 and 400ppm iron chronic DSS-treated and 400ppm iron untreated groups of animals.  
406 Previous research has established a reduction in the biodiversity of commensal bacteria in  
407 IBD (34). In mouse experiments, changes in bacterial composition resulted from colonic  
408 inflammation and infection (35). In particular, intestinal pathogens (some types of  
409 *Proteobacteria*) appeared to take advantage of this. This observation is in agreement with the  
410 'food hypothesis' and 'differential killing' hypothesis. These two mechanisms are likely to  
411 contribute to the loss of colonisation resistance in the inflamed gut (36). Nonetheless, the post-  
412 hoc analysis of our data revealed that one bacterial phylum (*Proteobacteria*) was increased  
413 significantly ( $P<0.01$ ) in the 100ppm iron and 400ppm iron DSS-treated and 400ppm iron  
414 untreated groups. *Bacteroidetes* decreased significantly ( $P<0.028$ ) in the 400ppm iron DSS-  
415 treated group.

416

417 Haller et al. (37) investigated the effects of dietary iron upon the microbiome. Eight bacterial  
418 families and nine bacterial genera were significantly ( $P<0.01$ ) affected by luminal iron (ferrous  
419 sulphate) deficiency. The genera *Bifidobacterium* ( $P<0.0018$ ), *Succinivibrio* ( $P<0.0027$ ),  
420 *Turicibacter* ( $P<0.0020$ ) and *Clostridium* ( $P<0.0017$ ) were significantly increased in mice fed  
421 an iron depleted diet, whereas the genera *Desulfovibrio* ( $P<0.0001$ ), *Dorea* ( $P<0.01$ ) and  
422 *Bacteroides* related were greatly reduced. The authors concluded that all significant  
423 differences in bacterial abundance in wild-type mice appeared as a result of the interaction  
424 between treatment and host-mediated inflammation (37, 38). There are several key  
425 differences between that paper and our own: they investigated caecal contents, not faeces;  
426 they induced ileitis, not colitis and they did not measure faecal iron concentration. Thus, their  
427 paper and our data cannot be directly compared.

428

429 Our data analysis showed that seven genera were significantly different. In the half standard  
430 iron diets (100ppm) DSS-treated group, we found reductions in *Lactobacillus* ( $P<0.002$ ),  
431 *Dorea*, *Clostridium*, *Bacteroides* and *Odoribacter* ( $P<0.04$ ), *Bilophila* ( $P<0.008$ ), and an

432 increase in (*Prevotella*  $P<0.008$ ), all belonging to three phyla [*Firmicutes*, *Bacteroidetes* and  
433 *Proteobacteria*]. In the 400ppm iron DSS group, a significant reduction was shown in  
434 *Lactobacillus* ( $P<0.01$ ). The only control group in which significant differences were found was  
435 the 400ppm iron group, where four phyla [*Firmicutes*, *Bacteroidetes*, *Proteobacteria*, and  
436 *Actinobacteria*] with seven genera showed statistically significant differences. Increases were  
437 shown in *Lactobacillus* ( $P<0.02$ ), *Oscillospira* ( $P<0.03$ ), *Adlercreutzia* and *Candidatus*  
438 *Arthromitus* ( $P<0.04$ ), whereas reductions occurred in *Bacteroides* ( $P<0.02$ ), *Bilophila*  
439 ( $P<0.03$ ) and *Ruminococcus* ( $P<0.04$ ) (Table 1-c).

440

441 Dietary iron plays a role in modulating the susceptibility to DSS-induced colitis. Lower (half  
442 standard) iron content in the diet significantly worsened acute colitis leading to an increase in  
443 faecal iron. Double standard iron diets caused a dysbiosis. These observations demonstrated  
444 the importance of luminal iron and inflammation. Manipulations in dietary iron administration  
445 for a longer period significantly exacerbated susceptibility towards developing DSS-induced  
446 intestinal inflammation suggesting that the time of iron supplementation may be crucial in  
447 aggravating colitis. We cannot explain why the reduced iron diet exacerbates colitis. Further  
448 studies will be necessary to investigate the relevance of our findings in humans.

449

450

451

452

453

454

455

456

457

458 **Supplementary:**

459 All data files uploaded in supporting information file.

460 

## References

461

462 1. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. *Annu Rev Immunol.*  
463 2010;28:573-621.

464 2. Constante M, Fragoso G, Lupien-Meilleur J, Calve A, Santos MM. Iron Supplements  
465 Modulate Colon Microbiota Composition and Potentiate the Protective Effects of Probiotics in  
466 Dextran Sodium Sulfate-induced Colitis. *Inflamm Bowel Dis.* 2017;23(5):753-66.

467 3. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al. Guidelines for the  
468 management of inflammatory bowel disease in adults. *Gut.* 2011;60(5):571-607.

469 4. Manfred Wick WP, Paul Lehmann. Clinical Aspects and Laboratory – Iron Metabolism.  
470 6th ed. SpringerWienNewYork: Springer Vienna; 2011.

471 5. Kulnigg S, Teischinger L, Dejaco C, Waldhor T, Gasche C. Rapid recurrence of IBD-  
472 associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin  
473 treatment. *Am J Gastroenterol.* 2009;104(6):1460-7.

474 6. Stein J, Dignass AU. Management of iron deficiency anemia in inflammatory bowel  
475 disease - a practical approach. *Ann Gastroenterol.* 2013;26(2):104-13.

476 7. Gasche C, Reinisch W, Lochs H, Parsaei B, Bakos S, Wyatt J, et al. Anemia in Crohn's  
477 disease. Importance of inadequate erythropoietin production and iron deficiency. *Dig Dis Sci.*  
478 1994;39(9):1930-4.

479 8. Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn's disease.  
480 *Aliment Pharmacol Ther.* 2006;24(11-12):1507-23.

481 9. Rizvi S, Schoen RE. Supplementation with oral vs. intravenous iron for anemia with  
482 IBD or gastrointestinal bleeding: is oral iron getting a bad rap? *Am J Gastroenterol.*  
483 2011;106(11):1872-9.

484 10. Weiss G, Wachter H, Fuchs D. Linkage of cell-mediated immunity to iron metabolism.  
485 *Immunol Today.* 1995;16(10):495-500.

486 11. Carrier J, Aghdassi E, Platt I, Cullen J, Allard JP. Effect of oral iron supplementation  
487 on oxidative stress and colonic inflammation in rats with induced colitis. *Aliment Pharmacol  
488 Ther.* 2001;15(12):1989-99.

489 12. Lobo V, Patil A, Phatak A, Chandra N. Free radicals, antioxidants and functional foods:  
490 Impact on human health. *Pharmacogn Rev.* 2010;4(8):118-26.

491 13. Erichsen K, Ulvik RJ, Grimstad T, Berstad A, Berge RK, Hausken T. Effects of ferrous  
492 sulphate and non-ionic iron-polymaltose complex on markers of oxidative tissue damage in  
493 patients with inflammatory bowel disease. *Aliment Pharmacol Ther.* 2005;22(9):831-8.

494 14. Kanneganti M, Mino-Kenudson M, Mizoguchi E. Animal models of colitis-associated  
495 carcinogenesis. *J Biomed Biotechnol.* 2011;2011:342637.

496 15. Comito D, Romano C. Dysbiosis in the pathogenesis of pediatric inflammatory bowel  
497 diseases. *Int J Inflam.* 2012;2012:687143.

498 16. Lombardi VR, Etcheverria I, Carrera I, Cacabelos R, Chacon AR. Prevention of chronic  
499 experimental colitis induced by dextran sulphate sodium (DSS) in mice treated with FR91. *J  
500 Biomed Biotechnol.* 2012;2012:826178.

501 17. O'Neil DA, Porter EM, Elewaut D, Anderson GM, Eckmann L, Ganz T, et al. Expression  
502 and regulation of the human beta-defensins hBD-1 and hBD-2 in intestinal epithelium. *Journal  
503 of immunology.* 1999;163(12):6718-24.

504 18. Jones DE, Bevins CL. Paneth cells of the human small intestine express an  
505 antimicrobial peptide gene. *The Journal of biological chemistry.* 1992;267(32):23216-25.

506 19. Elinav E, Strowig T, Kau AL, Henao-Mejia J, Thaiss CA, Booth CJ, et al. NLRP6  
507 inflammasome regulates colonic microbial ecology and risk for colitis. *Cell.* 2011;145(5):745-  
508 57.

509 20. Burrough ER, Arruda BL, Plummer PJ. Comparison of the Luminal and Mucosa-  
510 Associated Microbiota in the Colon of Pigs with and without Swine Dysentery. *Front Vet Sci.*  
511 2017;4:139.

512 21. Byrne FR, Viney JL. Mouse models of inflammatory bowel disease. *Curr Opin Drug  
513 Discov Devel.* 2006;9(2):207-17.

514 22. Bauer C, Duewell P, Mayer C, Lehr HA, Fitzgerald KA, Dauer M, et al. Colitis induced  
515 in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. *Gut*.  
516 2010;59(9):1192-9.

517 23. Ding S, Walton KL, Blue RE, McNaughton K, Magness ST, Lund PK. Mucosal healing  
518 and fibrosis after acute or chronic inflammation in wild type FVB-N mice and C57BL6  
519 procollagen alpha1(I)-promoter-GFP reporter mice. *PLoS One*. 2012;7(8):e42568.

520 24. Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Lozupone CA, Turnbaugh PJ,  
521 et al. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample.  
522 *Proc Natl Acad Sci U S A*. 2011;108 Suppl 1:4516-22.

523 25. Mahalhal A, Williams JM, Johnson S, Ellaby N, Duckworth CA, Burkitt MD, et al. Oral  
524 iron exacerbates colitis and influences the intestinal microbiome. *PLoS One*.  
525 2018;13(10):e0202460.

526 26. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, et al.  
527 QIIME allows analysis of high-throughput community sequencing data. *Nat Methods*.  
528 2010;7(5):335-6.

529 27. Edgar RC. Search and clustering orders of magnitude faster than BLAST.  
530 *Bioinformatics*. 2010;26(19):2460-1.

531 28. McDonald D, Price MN, Goodrich J, Nawrocki EP, DeSantis TZ, Probst A, et al. An  
532 improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses  
533 of bacteria and archaea. *ISME J*. 2012;6(3):610-8.

534 29. Califf K GA, Knight R, Caporaso JG. The human microbiome: getting personal.  
535 *Microbe*. 2014;9:410-5.

536 30. Matsuoka K, Kanai T. The gut microbiota and inflammatory bowel disease. *Semin  
537 Immunopathol*. 2015;37(1):47-55.

538 31. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel  
539 method in the induction of reliable experimental acute and chronic ulcerative colitis in mice.  
540 *Gastroenterology*. 1990;98(3):694-702.

541 32. Melgar S, Karlsson A, Michaelsson E. Acute colitis induced by dextran sulfate sodium  
542 progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms  
543 and inflammation. *Am J Physiol Gastrointest Liver Physiol.* 2005;288(6):G1328-38.

544 33. Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S, Mori H. A novel inflammation-  
545 related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium  
546 sulfate. *Cancer Sci.* 2003;94(11):965-73.

547 34. Packey CD, Sartor RB. Commensal bacteria, traditional and opportunistic pathogens,  
548 dysbiosis and bacterial killing in inflammatory bowel diseases. *Curr Opin Infect Dis.*  
549 2009;22(3):292-301.

550 35. Lupp C, Robertson ML, Wickham ME, Sekirov I, Champion OL, Gaynor EC, et al. Host-  
551 mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of  
552 Enterobacteriaceae. *Cell Host Microbe.* 2007;2(2):119-29.


553 36. Stecher B, Hardt WD. The role of microbiota in infectious disease. *Trends Microbiol.*  
554 2008;16(3):107-14.

555 37. Werner T, Wagner SJ, Martinez I, Walter J, Chang JS, Clavel T, et al. Depletion of  
556 luminal iron alters the gut microbiota and prevents Crohn's disease-like ileitis. *Gut.*  
557 2011;60(3):325-33.


558 38. Zimmermann MB, Chassard C, Rohner F, N'Goran E K, Nindjin C, Dostal A, et al. The  
559 effects of iron fortification on the gut microbiota in African children: a randomized controlled  
560 trial in Cote d'Ivoire. *Am J Clin Nutr.* 2010;92(6):1406-15.

561

**Figure 1-a:**



**Figure 1-b:**



**Figure 2-a:**




Figure 2-b:







Figure 3-a:




**Figure 3-b:**



**Figure 4:**




**Figure 5-a:**



bioRxiv preprint doi: <https://doi.org/10.1101/585174>; this version posted March 21, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

**Figure 5-b:**



**Figure 5-c:**

